What happened with PHG today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Philips supplies hospitals and health systems with equipment and software to diagnose illness, guide treatment and monitor patients. Diagnosis & Treatment is its largest business, including imaging systems and the Azurion platform for image-guided procedures. Connected Care, the next largest, provides patient monitoring, health informatics and sleep and respiratory care. Customers buy or lease equipment and pay for software and maintenance; disposable devices used in procedures and some usage-based contracts bring recurring revenue. Product sales remain the main source of revenue.
Philips also sells personal care, oral health, and mother and child care products. This smaller but substantial business earns mainly through deliveries to retailers and online platforms. Philips is expanding direct-to-consumer sales and subscriptions.
Regulatory compliance limits what its sleep and respiratory care business can sell. Under a US consent decree, Philips Respironics cannot sell new sleep therapy or other respiratory care devices in the United States until it meets the relevant requirements. It can still service installed devices and supply accessories, consumables and replacement parts. Outside the United States, sales of new devices continue subject to certain requirements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Philips’ results hinge on hospital investment in imaging and monitoring—watch Siemens Healthineers, an important rival missing here—and on the regulatory recovery of its Respironics business.
GE HealthCare and Philips compete for hospitals’ and health systems’ spending on diagnostic imaging, patient-care equipment and software. Watch GE HealthCare’s imaging sales for clues to the hospital spending that also matters to Philips.
Baxter and Philips compete for healthcare providers’ investment in patient monitoring, ECG and connected-care technology. Baxter’s monitoring and connected-care business is the part to watch for clues to demand facing Philips’ Connected Care segment.
Procter & Gamble competes for the same consumer spending as Philips: its Braun grooming devices and Oral-B devices rival Philips’ electric grooming and Sonicare oral-care products.
iRadimed Corporation competes directly with Philips’ Invivo systems in monitors that track patients’ vital signs during MRI scans, selling to hospitals and acute-care facilities. Its 3880 monitoring-system sales are the relevant line to watch, rather than its MRI infusion pumps.
Butterfly Network, Inc. competes with Philips for clinical imaging customers buying ultrasound equipment. Its handheld devices scan the whole body with one probe; adoption of those devices is the development to watch for Philips’ ultrasound business.
Church & Dwight competes for consumers’ oral-care spending through its Waterpik products, which rival Philips’ oral-healthcare devices.
Spectrum Brands Holdings, Inc. and Philips compete in branded grooming products sold through retailers and distributors. Watch Spectrum’s personal-care sales and retail relationships: Philips books most Personal Health revenue when products reach retailers and online platforms.
Colgate-Palmolive and Philips both sell toothbrushes to consumers, so purchasing habits and product innovation connect their oral-care businesses. Watch Colgate-Palmolive’s toothbrush offerings rather than treating its broader oral-care sales, which also include toothpaste and mouthwash, as a direct match for Philips.
Haemonetics competes with Philips in devices used to assess coronary artery function: its OpSens guidewires measure pressure and work with monitoring equipment, rivaling Philips’ coronary physiology assessment devices sold to hospitals.
Procter & Gamble Company earningsPG
Procter & Gamble’s report will show whether consumers are still buying grooming and oral-care devices in the product categories where it competes with Philips’ Personal Health business.
Focus on P&G’s Braun grooming devices and Oral-B devices, not its company-wide results. Resilient sales in those products would show that consumers are still spending in categories Philips also serves; weaker sales would point to pressure on demand for Philips’ Personal Health products, without proving how Philips itself performed.
GE HealthCare Technologies Inc. earningsGEHC
GE HealthCare’s imaging sales will show how much hospitals and health systems are spending on diagnostic equipment, the same customer budgets Philips competes for.
Focus on GE HealthCare’s imaging sales rather than treating all its businesses as a direct match. Stronger imaging sales would indicate that hospitals are sustaining purchases of diagnostic equipment, a favorable demand signal for Philips’ Diagnosis & Treatment business; weaker sales would suggest those customers’ equipment budgets are tightening.
Baxter International Inc. earningsBAX
Baxter’s patient-monitoring and connected-care sales will show how healthcare providers are spending in markets that also matter to Philips’ Connected Care business.
Watch Baxter’s monitoring and connected-care sales. Stronger sales would show that healthcare providers are still buying these technologies, a positive demand signal for Philips’ Connected Care business; weaker sales would suggest that the same kinds of customers may be slowing purchases.
Butterfly Network, Inc. earningsBFLY
Butterfly Network, Inc.’s report will show whether clinicians are adopting its handheld ultrasound devices, an alternative competing for customers with Philips’ ultrasound business.
Look for sales or adoption of Butterfly’s handheld ultrasound devices, not a direct comparison of company-wide results. Greater adoption would show that clinicians are taking up this alternative, making competition for Philips’ ultrasound business more consequential; limited adoption would suggest that this approach has not yet gained the same traction.
Church & Dwight Co., Inc. earningsCHD
Church & Dwight’s Waterpik sales will show consumer demand for oral-care devices that compete for spending with Philips’ oral-health products.
Focus on Waterpik sales, not Church & Dwight’s company-wide results. Stronger sales would show that consumers are still buying this type of oral-care device, a supportive demand signal for Philips’ overlapping products; weaker sales would suggest that spending in this category may be cooling.
KONINKLIJKE PHILIPS N.V. earningsThis company
Philips’ report will show whether hospitals and other customers are buying enough imaging, therapy and patient-care technology to lift sales and operating returns in those businesses.
Read sales for Diagnosis & Treatment and Connected Care alongside their Adjusted EBITA, a company-defined measure of operating performance. Rising sales with rising Adjusted EBITA would show that customer purchases and operational improvements are translating into stronger returns; weaker sales or Adjusted EBITA would show that demand, product mix or costs are still holding those businesses back.
Haemonetics Corporation earningsHAE
Haemonetics’ OpSens guidewire sales will show hospital demand for coronary-function assessment tools, a market where Philips also sells competing devices.
Focus on Haemonetics’ OpSens guidewire business, not its total sales. Stronger relevant sales would show that hospitals are still buying tools for coronary-function assessment, supporting demand for Philips’ competing devices; weaker sales would suggest purchases in this niche may be slowing.
